Business Context and Reporting Period
Promis Neurosciences Inc. (PMN) is a clinical-stage biopharmaceutical company developing antibody therapies for neurodegenerative diseases, including Alzheimer's disease (AD), multiple system atrophy (MSA), and amyotrophic lateral sclerosis (ALS). The company operates as a single segment and is classified as an Emerging Growth Company. This summary covers the quarterly period ended June 30, 2024 (Q2 2024).
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Balance Sheet (June 30, 2024) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2.62) million | $(6.26) million | N/A |
| Operating Expenses | $(2.71) million | $(6.39) million | N/A |
| Cash and Short-Term Investments | N/A | N/A | $1.02 million |
| Total Current Liabilities | N/A | N/A | $3.17 million |
| Accumulated Deficit | N/A | N/A | $(99.72) million |
| Net Cash Used in Operating Activities | N/A | $(11.80) million | N/A |
Note: The company has no revenue. Operating expenses consist primarily of Research and Development (R&D) and General and Administrative (G&A) costs.
Material Changes vs. Prior Period
- Net Loss Improvement (YTD): The net loss for the six months ended June 30, 2024, decreased by $1.01 million (14%) compared to the same period in 2023, driven by reduced operating expenses.
- Expense Reduction: Total operating expenses decreased by $1.48 million year-over-year. R&D expenses fell by $0.77 million due to lower consulting fees following the completion of the PMN310 IND application. G&A expenses decreased by $0.71 million, excluding one-time costs in the prior year related to abandoned financing.
- Cash Position: Cash and cash equivalents declined significantly from $12.60 million at December 31, 2023, to $0.99 million at June 30, 2024. This reduction was primarily due to a $5.9 million repayment of previously deferred accounts payable in March 2024 and ongoing operating losses.
- Other Income: Other income decreased by $0.47 million year-over-year, largely due to a lower gain on the change in fair value of financial instruments (warrant liabilities).
Outlook, Risks, and Subsequent Events
- Private Placement (Subsequent Event): In July 2024, the company completed a private placement raising $30.3 million in gross proceeds. Management believes these net proceeds will fund operations into 2026.
- Clinical Progress: Topline data from the first four cohorts of the PMN310 Phase 1a trial were released in July 2024, showing the drug was well-tolerated and crossed into the central nervous system. A Phase 1b proof-of-concept trial in AD patients is expected to initiate in the second half of 2024.
- Liquidity Risk: Prior to the July financing, the company had a negative working capital position and an accumulated deficit of $99.7 million. The company remains dependent on additional financing to continue operations and advance clinical trials.
- Share Capital: The July 2024 financing triggered the mandatory conversion of all 1,166,667 Series 2 Convertible Preferred Shares into Common Shares.
Investor Verification Checklist
- Runway Confirmation: Verify the closing of the July 2024 private placement and confirm the net proceeds received to validate the management's assertion of funding through 2026.
- Debt Settlement: Confirm the full repayment of the $5.9 million deferred accounts payable to ensure no lingering contingent liabilities or vendor disputes.
- Warrant Liability Valuation: Review the fair value assumptions (volatility, risk-free rate) used for the remaining warrant liabilities, as changes in these inputs significantly impact net income/loss.
- Clinical Milestones: Monitor the initiation of the Phase 1b trial for PMN310 and the timing of the 6-month and 12-month data readouts, which are tied to the exercise of Tranche A and B warrants from the recent financing.
- Share Dilution: Assess the impact of the new Common Share Units and Pre-Funded Warrants issued in July 2024 on existing shareholder ownership percentages.